| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
OPKO Health Inc (TA: OPK)
OPK Technical Analysis
5
| As on 11th Jun 2023 OPK SHARE Price closed @ 562.40 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 961.00 & Strong Sell for SHORT-TERM with Stoploss of 1241.67 we also expect STOCK to react on Following IMPORTANT LEVELS. |
OPKSHARE Price
| Open | 562.00 | Change | Price | % |
| High | 577.80 | 1 Day | -27.60 | -4.68 |
| Low | 562.00 | 1 Week | 57.50 | 11.39 |
| Close | 562.40 | 1 Month | 45.20 | 8.74 |
| Volume | 178514 | 1 Year | -642.60 | -53.33 |
| 52 Week High 1596.00 | 52 Week Low 375.50 | ||||
TA Israel Most Active Stocks
| TA125 | 2008.05 | 1.06% |
| BEZQ | 472.70 | -0.06% |
| GLEX | 8.50 | 10.39% |
| CANF | 3.20 | -3.03% |
| GIVO-L | 47.30 | 0.00% |
| LUMI | 2815.00 | 1.26% |
| ELAL | 394.00 | 3.55% |
| GNRS | 78.90 | 1.41% |
| BLRX | 37.60 | -2.08% |
| TDGN-L | 171.50 | 17.55% |
TA Israel Top Gainers Stocks
TA Israel Top Losers Stocks
| OPK Daily Charts |
OPK Intraday Charts |
Whats New @ Bazaartrend |
OPK Free Analysis |
|
|
OPK Important Levels Intraday
| RESISTANCE | 592.85 |
| RESISTANCE | 583.08 |
| RESISTANCE | 577.05 |
| RESISTANCE | 571.01 |
| SUPPORT | 553.79 |
| SUPPORT | 547.75 |
| SUPPORT | 541.72 |
| SUPPORT | 531.95 |
OPK Forecast April 2024
| 4th UP Forecast | 1996.09 |
| 3rd UP Forecast | 1536.3 |
| 2nd UP Forecast | 1252.09 |
| 1st UP Forecast | 967.88 |
| 1st DOWN Forecast | 156.92 |
| 2nd DOWN Forecast | -127.29 |
| 3rd DOWN Forecast | -411.5 |
| 4th DOWN Forecast | -871.29 |
OPK Weekly Forecast
| 4th UP Forecast | 1011.39 |
| 3rd UP Forecast | 867.40 |
| 2nd UP Forecast | 778.39 |
| 1st UP Forecast | 689.39 |
| 1st DOWN Forecast | 435.42 |
| 2nd DOWN Forecast | 346.41 |
| 3rd DOWN Forecast | 257.40 |
| 4th DOWN Forecast | 113.41 |
OPK Forecast2024
| 4th UP Forecast | 3059.98 |
| 3rd UP Forecast | 2258.99 |
| 2nd UP Forecast | 1763.88 |
| 1st UP Forecast | 1268.77 |
| 1st DOWN Forecast | -143.97 |
| 2nd DOWN Forecast | -639.08 |
| 3rd DOWN Forecast | -1134.19 |
| 4th DOWN Forecast | -1935.18 |
OPKO Health Inc ( TA Israel Symbol : OPK )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
OPK Business Profile
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units, as well as 4Kscore prostate cancer testing services. The company's Pharmaceutical segment offers Rayaldee for treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. It also specialty active pharmaceutical ingredients; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, the company operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. OPKO Health, Inc. was incorporated in 1991 and is headquartered in Miami, Florida. Address: 4400 Biscayne Boulevard, Miami, FL, United States, 33137
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service